Comparison between Whole and Intact Parathyroid Hormone Assays

Therapeutic Apheresis and Dialysis

Volumn 15, Issue SUPPL.1, 2011, Pages 42-49

  Taniguchi, Masatomo ^a   Tanaka, Motoko ^b   Hamano, Takayuki ^o   Nakanishi, Shohei ^c   Fujii, Hideki ^d   Kato, Hitoshi ^e   Koiwa, Fumihiko ^f   Ando, Ryoichi ^g   Kimata, Naoki ^h   Akiba, Takashi ^h   Kono, Takashi ^j   Yokoyama, Keitaro ⁱ   Shigematsu, Takashi ^k   Kakuta, Takatoshi ^l   Kazama, Junichiro James ^m   Tominaga, Yoshihiro ⁿ   Fukagawa, Masafumi ^l  

^a KYUSHU UNIVERSITY   (Japan)

^b Akebono Clinic   (Japan)

^c Department of Internal Medicine   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^g MUSASHINO RED CROSS HOSPITAL   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j Mihama Narita Clinic   (Japan)

^k WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^l TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

ⁿ NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Intact parathyroid hormone; N parathyroid hormone; Non 1 84 parathyroid hormone; Whole parathyroid hormone

Indexed keywords

PARATHYROID HORMONE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HEMODIALYSIS PATIENT; HORMONE DETERMINATION; HUMAN; INTERMETHOD COMPARISON; JAPANESE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; VALIDATION PROCESS;

AGED; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; JAPAN; MALE; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RENAL DIALYSIS;

EID: 79956202270     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00926.x     Document Type: Article

References (28)

1. Brossard JH, Cloutier M, Roy L etal. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-9.
2. Lepage R, Roy L, Brossard JH etal. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-9.
3. Brossard JH, Lepage R, Cardinal H etal. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000;46:697-703.
4. Gao P, Scheibel S, D'Amour P etal. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14.
5. Coen G, Bonucci E, Ballanti P etal. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002;40:348-54.
6. John MR, Goodman WG, Gao P etal. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-90.
7. Slatopolsky E, Finch J, Clay P etal. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753-61.
8. Monier-Faugere MC, Geng Z, Mawad H etal. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001;60:1460-8.
9. Nguyen-Yamamoto L, Rousseau L, Brossard JH etal. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001;142:1386-92.
10. Divieti P, John MR, Juppner H etal. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1PTH/PTHrP receptor. Endocrinology 2002;143:171-6.
11. Goodman WG, Salusky IB, Juppner H. New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments. Nephrol Dial Transplant 2002;17:1731-6.
12. Holmes DT, Levin A, Forer B etal. Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem 2005;51:915-7.
13. Payne RB, Little AJ, Williams RB etal. Interpretation of serum calcium levels in patient with abnormal serum proteins. Br Med J 1973;4:643-6.
14. D'Amour P, Brossard JH, Rakel A etal. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49:2037-44.
15. Komaba H, Shin J, Fukagawa M. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. Nephrol Dial Transplant 2010;25:638-41.
16. Arakawa T, D'Amour P, Rousseau L etal. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol 2006;1:525-31.
17. Nakanishi S, Kazama JJ, Shigematsu T etal. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 2001;38(Suppl 1):S172-S174.
18. Fujimori A, Sakai M, Yoshiya K etal. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. Ther Apher Dial 2004;8:474-9.
19. Reichel H, Esser A, Roth HJ etal. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003;18:759-68.
20. Kazama JJ, Omori T, Ei I etal. Circulating 1-84PTH and large C-terminal PTH fragment levels in uremia. Clin Exp Nephrol 2003;7:144-9.
21. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-25.
22. D'Amour P, Palardy J, Bahsali G etal. The modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration. J Clin Endocrinol Metab 1992;74:525-32.
23. Brossard JH, Whittom S, Lepage R etal. Carboxyl-terminal fragments of parathyroid hormone are not secreted preferentially in primary hyperparathyroidism as they are in other hypercalcemic conditions. J Clin Endocrinol Metab 1993;77:413-9.
24. Cloutier M, Rousseau L, Gascon-Barre M etal. Immunological evidences for post-translational control of the parathyroid function by ionized calcium in dogs. Bone Miner 1993;22:197-207.
25. Melamed ML, Eustace JA, Plantinga LC etal. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008;23:1650-8.
26. Lehmann G, Stein G, Huller M etal. Specific measurement of PTH(1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005;68:1206-14.
27. Santamaria R, Almaden Y, Felsenfeld A etal. Dynamics of PTH secretion in hemodialysis patients as determined by the intact and whole PTH assays. Kidney Int 2003;64:1867-73.
28. Tanno Y, Yokoyama K, Nakayama M etal. IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker. Nephrol Dial Transplant 2003;18(Suppl 3):iii97-iii98.